海思科：子公司获得创新药IND申请受理通知书

Core Viewpoint - Company Haisco (002653.SZ) has received clinical trial acceptance notifications from the National Medical Products Administration for two new drug candidates, HSK50042 and HSK55879, indicating progress in its drug development pipeline [2]. Group 1: Drug Development - HSK50042 is an oral, potent, and highly selective small molecule inhibitor intended for the treatment of respiratory system diseases [2]. - HSK55879 is an oral small molecule agonist aimed at treating metabolic system diseases [2]. - Both drug candidates are classified as Category 1 chemical drugs [2].